Overview

Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma

Status:
RECRUITING

Trial end date:
2027-08-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical trial is to determine the maximum tolerated dose and the recommended phase II dose for nab-paclitaxel when administered concurrently with radiotherapy in nasopharyngeal carcinoma. Researchers will observe the toxicity response of patients receiving nab-paclitaxel at 180 mg/m, 200 mg/m, 230 mg/m, and 260 mg/m.

Phase:

PHASE1

Details

Lead Sponsor:

Sun Yat-sen University

Treatments:

130-nm albumin-bound paclitaxel